What is the current Price Target for the Pieris Pharmaceuticals, Inc. stock?

The average Pieris Pharmaceuticals, Inc. target price is $49.98. This is 81.42% higher than the current stock price. The highest price target is 166.79%, the lowest is 39.31%. 11 Analysts have issued a price target Pieris Pharmaceuticals, Inc. 2026 .

How high will the Pieris Pharmaceuticals, Inc. stock rise?

No reliable answer can be given as to how high the Pieris Pharmaceuticals, Inc. stock will rise. The performance of stocks, including the Pieris Pharmaceuticals, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Pieris Pharmaceuticals, Inc. stock today?

The performance of Pieris Pharmaceuticals, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Pieris Pharmaceuticals, Inc. stock fall?

The decline in Pieris Pharmaceuticals, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Pieris Pharmaceuticals, Inc. Forecast, price target & analysts

$28.07

1.87% today

Nasdaq, Jul 15, 07:46 pm CET

ISIN

US7207951036

Symbol

PVLA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Pieris Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Pieris Pharmaceuticals, Inc. Classifications & Recommendation:

Buy

93%

Hold

Pieris Pharmaceuticals, Inc. Price Target

Target Price	$49.98
Price	$27.55
Potential	81.42% register free of charge
Number of Estimates	11

	11 Analysts have issued a price target Pieris Pharmaceuticals, Inc. 2026 . The average Pieris Pharmaceuticals, Inc. target price is $49.98. This is 81.42% register free of charge higher than the current stock price. The highest price target is $73.50 166.79% register free of charge , the lowest is $38.38 39.31% register free of charge .
	A rating was issued by 15 analysts: 14 Analysts recommend Pieris Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Pieris Pharmaceuticals, Inc. stock has an average upside potential 2026 of 81.42% register free of charge . Most analysts recommend the Pieris Pharmaceuticals, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-7.62	-3.01
	65.05%	60.50%
P/E		negative

11 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast for earnings per share. The average Pieris Pharmaceuticals, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-7.62	65.05%
2025	$-3.01 60.50% Unlock
2026	$-3.15 4.65% Unlock
2027	$-4.30 36.51% Unlock

Current	-14.65	3,821.41%
2025	-9.15 37.56% Unlock
2026	-8.75 4.37% Unlock
2027	-6.41 26.74% Unlock

Pieris Pharmaceuticals, Inc....

Current Pieris Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Canaccord Genuity	Locked ➜ Locked	Locked	May 16 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 30 2025
Chardan Capital	Locked ➜ Locked	Locked	Apr 09 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 01 2025
Stifel	Locked ➜ Locked	Locked	Mar 26 2025
Jones Trading	Locked ➜ Locked	Locked	Mar 25 2025
Scotiabank	Locked ➜ Locked	Locked	Mar 07 2025

Analyst Rating	Date
Locked Canaccord Genuity: Locked ➜ Locked	May 16 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 30 2025
Locked Chardan Capital: Locked ➜ Locked	Apr 09 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 01 2025
Locked Stifel: Locked ➜ Locked	Mar 26 2025
Locked Jones Trading: Locked ➜ Locked	Mar 25 2025
Locked Scotiabank: Locked ➜ Locked	Mar 07 2025

Discover more stocks with a high price target

Novo Nordisk 48.37%

Alibaba Group Holding Ltd 43.59%

Deutsche Telekom 28.30%

Adidas 27.93%

BioNTech SE - ADR 26.35%

Tencent Holdings Ltd. 25.16%

Apple 14.90%

Siemens 14.01%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now